CAPA Blasts STRONGER Patents Act As A Massive Concession To Big Pharma

Coalition urges Congress to reject harmful bill removing oversight review process currently used to protect against Big Pharma’s rampant patent abuse leading to significant higher prescription drug prices for patients

WASHINGTON, D.C. – The Coalition Against Patent Abuse, a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free market advocates and others released the following statement outlining its opposition to the STRONGER (Support Technology & Research for Our Nation’s Growth and Economic Resilience) Patents Act of 2019 that was re-introduced today by U.S. Senators Chris Coons (D-DE) and Tom Cotton (R-AR) and U.S. Representatives Bill Foster (D-IL) and Steve Stivers (R-OH). This legislation would significantly restrict the USPTO’s inter partes review (IPR) process which is a vital consumer protection to combat Big Pharma’s patent abuse practices and the industry’s price gouging of patients across the country.

The following statements are attributable to Mathew Lane, Executive Director of the Coalition Against Patent Abuse:

“CAPA is disappointed in the efforts of Senators Coons and Cotton and Representatives Foster and Stivers to limit the ability of the public to challenge Big Pharma’s manipulative patent abuse that is a major contributing factor to rising prescription drugs.”

“At a time when Big Pharma is using deceptive tricks, like product-hopping and creating patent thickets, to game the patent system it is remarkably irresponsible to effectively end a critical tool in the fight against patent abuse.  IPR is a faster, more accessible and less expensive way for the public to bring evidence to the patent office that a patent shouldn’t have been issued and end a bad patent. It should be strengthened, not weakened.”

“This legislation is an inconceivable gift to Big Pharma and empowers them to continue abusing the patent system at the expense of American patients. If the public is prevented from challenging invalid patents, Big Pharma will be enabled to maintain and expand their drug monopolies and keep patients from accessing more affordable alternative medicines and treatments.”

“We strongly urge Congress to oppose this disastrous legislation. Our Coalition will continue working with members of both parties to enact responsible solutions that put American patients first, promote innovation and prevent Big Pharma from continuing to abuse the patent system.”

For more information, please visit